Neurones S.A.
NRO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.95 | 1.96 | 1.24 | 1.07 |
| FCF Yield | 6.78% | 5.10% | 4.66% | 6.31% |
| EV / EBITDA | 9.10 | 8.35 | 8.05 | 9.06 |
| Quality | ||||
| ROIC | 11.51% | 12.00% | 12.41% | 10.96% |
| Gross Margin | 47.97% | 46.78% | 12.27% | 12.03% |
| Cash Conversion Ratio | 1.33 | 1.23 | 1.24 | 1.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.79% | 8.52% | 8.25% | 4.37% |
| Free Cash Flow Growth | 33.74% | 22.02% | -23.70% | -5.97% |
| Safety | ||||
| Net Debt / EBITDA | -3.31 | -2.63 | -2.67 | -3.02 |
| Interest Coverage | 47.36 | 52.90 | 42.80 | 63.74 |
| Efficiency | ||||
| Inventory Turnover | 1,579.00 | 556.30 | 1,653.67 | 575.13 |
| Cash Conversion Cycle | 47.38 | 62.10 | 78.83 | 77.91 |